Stock Picks

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 03/27/2017 – 03/31/2017:

1) GALE – Galena Biopharma Inc
a. Buy at < ~ $0.53
b. Sell at >~ $3.15

2) GNMX – Medgenics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

3) TKAI – Tokai Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $0.73
b. Sell at >~ $1.80
c. Catalysts:
1. Merger with Otic Pharma Ltd; 20170101; 20170630; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5
2. Merger may be terminated if the Otic Transaction is not consummated by April 30, 2017; 20170301; 20170430; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5

4) NVGN – Novogen Limited (ADR)
a. Buy at < ~ $1.36
b. Sell at >~ $3.22
c. Catalysts:
1. Cantrixil started phase 1 clinic late last year.; 20161231; ; http://stocktwits.com/message/78192678
2. Anisina finishing up preclinical. Waiting on tox report. Trilexium is preclinical.; 20170101; ; http://stocktwits.com/message/78192678
3. GDC-0084 in phase 2 clinic sometime this year.; 20170301; 20171231; http://stocktwits.com/message/78192678

5) CYCC – Cyclacel Pharmaceuticals Inc
a. Buy at < ~ $3.15
b. Sell at >~ $5.60
c. Catalysts:
1. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
2. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3
3. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11

6) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $1.65
b. Sell at >~ $2.50
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. “@PeyoteBetting Hopefully a permission from EMA for sale of Paclical in Europe. Meeting scheduled in March”; 20170301; 20170331;
3. European approvals expected during spring 2017 for indications ovarian cancer & metastatic breast cancer; 20170301; 20170630; http://stocktwits.com/message/77020751

7) MICT – Micronet Enertec Technologies Inc – Trading Below Cash
a. Buy at < ~ $1.14
b. Sell at >~ $1.58

8) PRTO – Proteon Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $1.55
b. Sell at >~ $2.60
c. Catalysts:
1. Phase 3 enrollment to be completed 1Q 2017. Data due 2Q 2018. – Vonapanitase (PRT-201) PATENCY-2 – Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) – Phase 3; 20170101; 20170331; http://ir.proteontherapeutics.com/phoenix.zhtml?c=253625&p=irol-newsArticle&ID=2229192
3. Phase 3 enrollment to be completed 1Q 2017. Data due 2Q 2018. – Vonapanitase (PRT-201) PATENCY-2 – Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) – Phase 3; 20180401; 20180630; http://ir.proteontherapeutics.com/phoenix.zhtml?c=253625&p=irol-newsArticle&ID=2229192
4. A new clinical trial … hopes to enroll 500 before the end of 2017; 20170317; 20171231; http://www.bizjournals.com/kansascity/news/2017/03/17/proteon-therapeutics-vonapanitase-new-stage3-trial.html?ana=yahoo

9) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.17
b. Sell at >~ $2.45

10) SPRT – Support.com, Inc. – Trading Below Cash
a. Buy at < ~ $2.00
b. Sell at >~ $2.64

11) GENE – Genetic Technologies Limited (ADR)
a. Buy at < ~ $1.04
b. Sell at >~ $2.70
c. Catalysts:
1. Genetic Technologies is expected to post its validation study for the test within six months; 20170101; 20170630; http://seekingalpha.com/article/4033099-genetic-technologies-catalysts-tremendous-upside

12) TROV – TrovaGene Inc – Trading Below Cash
a. Buy at < ~ $0.95
b. Sell at >~ $1.50

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 03/27/2017 - 03/31/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 04/03/2017 – 04/07/2017:

1) GALE – Galena Biopharma Inc
a. Buy at < ~ $0.53
b. Sell at >~ $3.15

2) TNDM – Tandem Diabetes Care Inc
a. Buy at < ~ $1.10
b. Sell at >~ $3.00

3) GNMX – Medgenics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

4) TKAI – Tokai Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $0.73
b. Sell at >~ $1.80
c. Catalysts:
1. Merger with Otic Pharma Ltd; 20170101; 20170630; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5
2. Merger may be terminated if the Otic Transaction is not consummated by April 30, 2017; 20170301; 20170430; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5

5) AVEO – AVEO Pharmaceuticals, Inc.
a. Buy at < ~ $0.50
b. Sell at >~ $0.97
c. Catalysts:
1. Phase 3 enrollment to be completed June 2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170601; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
2. initial results from the Opdivo combination TiNivo study in RCC in the first half of 2017; 20170401; 20170630; https://seekingalpha.com/instablog/44479986-leny-hettmansperger/4974435-aveo-59c-insiders-recently-purchased-almost-10m-share-lots-significant-catalysts-upside-ahead?uprof=45&isDirectRoadblock=true
3. Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017. – Tivozanib + Opdivo – Renal cell cancer (RCC) – Phase 1/2; 20170630; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255714
4. Top-line data due 1Q 2018. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20180101; 20180331; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
5. Futility analysis due mid-2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170630; 20170930; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868

6) CYCC – Cyclacel Pharmaceuticals Inc
a. Buy at < ~ $3.15
b. Sell at >~ $5.60
c. Catalysts:
1. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
2. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3
3. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11

7) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $1.65
b. Sell at >~ $2.50
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. European approvals expected during spring 2017 for indications ovarian cancer & metastatic breast cancer; 20170301; 20170630; http://stocktwits.com/message/77020751

8) MICT – Micronet Enertec Technologies Inc – Trading Below Cash
a. Buy at < ~ $1.12
b. Sell at >~ $1.58

9) PRTO – Proteon Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $1.55
b. Sell at >~ $2.60
c. Catalysts:
2. A new clinical trial … hopes to enroll 500 before the end of 2017; 20170317; 20171231; http://www.bizjournals.com/kansascity/news/2017/03/17/proteon-therapeutics-vonapanitase-new-stage3-trial.html?ana=yahoo
3. Phase 3 enrollment to be completed 1Q 2017. Data due 2Q 2018. – Vonapanitase (PRT-201) PATENCY-2 – Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) – Phase 3; 20180401; 20180630; http://ir.proteontherapeutics.com/phoenix.zhtml?c=253625&p=irol-newsArticle&ID=2229192

10) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.17
b. Sell at >~ $2.45

11) DMTX – Dimension Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $1.65
b. Sell at >~ $2.20

12) SPRT – Support.com, Inc. – Trading Below Cash
a. Buy at < ~ $2.00
b. Sell at >~ $2.64

13) OPHT – Ophthotech Corp
a. Buy at < ~ $3.24
b. Sell at >~ $4.18
c. Catalysts:
1. After the Fovista trial with Avastin/Eylea is finished (some time in 1H17); 20170101; 20170630; https://seekingalpha.com/article/4057593-buy-ophthotech-get-cash-zimura-free
2. The catalyst would be an interim analysis of the Zimura Phase 2/3 trial which should occur some time between 2H2017 and 2H2018; 20170701; 20181231; https://seekingalpha.com/article/4057593-buy-ophthotech-get-cash-zimura-free

14) TROV – TrovaGene Inc – Trading Below Cash
a. Buy at < ~ $0.95
b. Sell at >~ $1.50

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 04/03/2017 - 04/07/2017, and Why?

[Author]

Posts